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Abstract
Background: There are very few reports of Aspergillus fumigatus causing endogenous endophthalmitis (EAE) in
immunocompetent individuals although it is well recognised in the immunocompromised. Treatment can be with
intravitreal, intravenous and oral antifungal agents. The benefit of an oral agent is clear however the concentration
of voriconazole in the inflamed eye after oral administration has not previously been documented.
Case presentation: We present a case of EAE in an immunocompetent 78-year-old Caucasian female who was
subsequently managed with oral voriconazole. Using a bioassay, we show an appropriate voriconazole
concentration in serum and vitreous samples.
Conclusion: This case adds to the limited literature on the prevalence of endogenous endophthalmitis in
immunocompetent patients and supports the use of voriconazole in such cases.
Background
Endogenous Aspergillus Endophthalmitis (EAE) is a con-
dition most commonly seen in patients who are immu-
nosuppressed. There are only five reports in the
literature of the condition in immunocompetent indivi-
duals. Loss of visual acuity is a common presentation
and patients frequently lose sight in the affected eye,
particularly if there is a delay in instituting appropriate
therapy. Voriconazole and other new anti-fungal agents
are likely to play an increasing role in treating this
condition.
Case presentation
A 78-year-old white caucasian lady presented to her
local hospital with rapid loss of vision in her right eye
over 12 hours. She had been suffering from non-specific
joint pains for several months for which she had been
receiving acupuncture. Ten days prior to her admission
a rheumatologist had diagnosed polymyalgia rheumatica
based on her symptomatology and scalp tenderness, but
she had not been started on steroid treatment. She had
had an anterior resection for adenocarcinoma of the
bowel in 2001 and a computed tomography scan six
months previously showed no evidence of tumour recur-
rence. There was a past medical history of melanoma
(resected from her right foot) in 1983, and a transient
ischaemic attack but had no history of diabetes, ocular
trauma or sinusitis. There had been no recent hospital
admissions or medical procedures.
Initial examination revealed a reduction in her visual
acuity on the right to hand movements only, there was
also tenderness over the right temporal artery. The left
eye vision was normal. The right fundus seen with a
direct ophthalmoscope showed an elevated, yellow, sub
retinal macular lesion with associated retinal haemor-
rhages and cotton wool spots. There was no evidence of
uveitis. The physical examination was otherwise normal.
At this time her erythrocyte sedimentation rate was 58
mm/hr, her C reactive protein 1 mg/L, total white cell
count of 11.9 × 10
9/L. Giant cell arteritis was suspected
to be the cause of her pain and she was commenced on
80 mg of prednisolone daily. After five days the pain
worsened and became more localised to the right eye
and she developed panuveitis with 1 mm hypopyon in
the anterior chamber. She was transferred to our insti-
tute for further management. An ultrasound B scan of
the eye showed retinal elevation at the macula, choroidal
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any medium, provided the original work is properly cited.thickening and subretinal fluid suggesting the diagnosis
of endogenous endophthalmitis. A vitreous biopsy was
performed which showed the macular lesion to orginate
from a subretinal mass accompanied by an area of
macular retinitis with intense inflammatory exudate in
the posterior vitreous. Intravitreal ceftazidime and van-
comycin were administered. The Gram stain of the vitr-
eous biopsy showed moderate numbers of neutrophils,
branching septate hyphae and no bacteria (Figure 1).
Bacterial cultures were negative but culture on Sabour-
aud’s agar revealed a mould identified as Aspergillus
fumigatus on the basis of typical colonial and micro-
scopic morphology. The organism was susceptible to
voriconazole (MIC 0.25 μg/ml) using the Clinical and
Laboratory Standards Institute MS27-A2 method[1]. She
was commenced on oral voriconazole 400 mg twice a
day for 24 hours as a loading dose. The following day
she complained of visual hallucinations at night, a well-
known side effect of the drug and the agent was discon-
tinued for a day. She subsequently tolerated mainte-
nance treatment at a dose of 200 mg 12 hourly to
complete a two-week course. Systemic steroids were
tapered and discontinued over two weeks. Six days after
commencing voriconazole she underwent a second vitr-
eous biopsy with intravitreal injection of 5 mcg of
amphotericin B. Gram stain and culture of this sample
were negative. Voriconazole levels were measured in
serum and vitreous aspirate, both eight hours after her
last 200 mg dose, by means of a bioassay. Both the assay
of the serum and the vitreous revealed a concentration
of 0.69 μg/ml.
An extensive search for a source of her infection
(blood cultures, echocardiogram, computed tomography
of chest, abdomen and pelvis and magnetic resonance
imaging of the brain) was negative. The uveitis
improved substantially during the first week of treat-
ment, but there was no improvement in her visual
acuity due to the macular involvement. On review two
months later the uveitis had settled, but there was per-
sistent pain and low intraocular pressure (4 mmHg) in
the right eye indicating the onset of phthisis bulbi. She
was blind in the right eye. Therefore enucleation of the
right eye was suggested and the patient consented to
the procedure. Histological examination of the enu-
cleated eye showed non-specific chronic fibrosing vitritis
with no fungal elements seen using special stains.
Discussion
A review of the literature revealed only five other cases
of endogenous Aspergillus endophthalmitis (EAE) in
immunocompetent patients [2-6].
Recognised risk factors include a history of immuno-
compromise, malignancy, organ transplantation, long
term corticosteroid use, drug abuse, ocular surgery,
trauma, endocarditis and chronic obstructive airways
disease [3,5-8].
A comprehensive search for a portal of entry or a
further focus of Aspergillus infection was conducted in
our case to no avail. Interestingly, as in our patient,
three of the reported immunocompetent cases had been
treated with corticosteroids for their symptoms prior to
a diagnosis being made [3-5]. It would be reasonable to
assume that this administration in the absence of an
anti fungal agent may have worsened the condition.
Poor outcome in the context of EAE is well recognised.
In the largest review of EAE [8], the outcomes with
intravitreal and intravenous antifungal agents only 8% (n
= 84) regained useful visual acuity. The propensity of
Aspergillus for the macula region in the retina was
directly correlated to poor visual outcome in these stu-
dies [8,9].
Voriconazole is a second generation synthetic deriva-
tive of fluconazole. It has a 96% oral bioavailability and
reaches peak plasma concentrations two to three hours
after oral dosing [7].
The ocular penetration of voriconazole was examined
in 14 patients undergoing elective pars plana vitrec-
tomies[10]. The voriconazole concentrations measured
two to three hours after two oral doses of 200 mg were
2.13 +/- 0.93 μg/ml (serum), 0.81 +/- 0.31 μg/ml (vitr-
eous) and 1.13 +/- 0.57 μg/ml (aqueous). Although our
levels were measured eight hours after the last dose of
voriconazole and a different assay was used, the vitreous
concentration was similar to that in the above study and
equivalent to the serum level. These results suggest that
the ocular penetration of voriconazole may be enhanced
in the context of endophthalmitis where there is a break
in the blood aqueous and retinal barrier. We postulate
this as the reason for enhanced permeability of the drug
into the eye to match serum concentrations. The vorico-
nazole concentration measured in our case was above Figure 1 Gram Stain of first vitreous aspirate.
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μg/ml). Voriconazole is an attractive agent for treatment
of fungal endophthalmitis; it has a broad spectrum of
activity, it can be given orally, and although visual side
effects are common, they usually resolve after the first
week of treatment. Amphotericin B, by contrast, can
only be given parenterally and may be toxic when admi-
nistered intravitreally. Another promising agent is cas-
pofungin possibly in conjunction with voriconazole.
Conclusion
This report adds to the small number of published cases
of EAE in the absence of known risk factors. We have
also shown enhanced intraocular penetration of vorico-
nazole in the context of endophthalmitis demonstrating
the potential role of the drug in treating infection and
limiting the progression of the disease. The poor out-
come, however, highlights the problems encountered in
treating Endogenous Aspergillus Endophthalmitis and
emphasises the need for early diagnosis and appropriate
institution of systemic antifungal therapy.
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